POLY MEDICURE Q2 FY27 CONCALL: RAISES FY27 STANDALONE EBITDA MARGIN GUIDANCE TO 26–27.5% FROM 25–27% 🟢🟢; MAINTAINS CONSOLIDATED REVENUE GUIDANCE AT ₹2,300–2,400 CR & EBITDA MARGIN AT 23–25%; TARGETS DOUBLING REVENUE BY FY30, ₹200–225 CR FY27 CAPEX & $15–25 MN U.S. SALES IN 3–4 YEARS